People usually search for this
BPC-157/TB-500/KPV/GHK-Cu 10+10+10+50mg (KLOW blend 80mg)
$225.00
Products will arrive in a lyophilized (powder) form for maximum stability
The KLOW blend combines four repair peptides — BPC-157, TB-500, KPV, and GHK-Cu — in a single co-lyophilized vial, adding anti-inflammatory KPV signaling to the GLOW trio's repair mechanisms. The four-component design targets parallel pathways across angiogenesis, cell migration, inflammation, and ECM remodeling. Supplied as a 10+10+10+50mg blended vial at ≥99% HPLC purity per component, for research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
BPC+TB500+GHK-Cu+KPV
SYNONYMS
KLOW blend
CAS NUMBER
137525-51-0 (BPC-157), 77591-33-4 (TB500), 300801-03-0 (GHK-Cu), 2828433-34-5 (KPV)
MOLECULAR FORMULA
C62H98N16O22 (BPC-157), C212H350N56O78S (TB500), C28H46CuN12O8 (GHK-Cu), C18H34N4O6 (KPV)
MOLECULAR WEIGHT
~7189 g/mol
STRUCTURE
Multi-peptide blend
PEPTIDE SEQUENCE
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (BPC-157), Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (TB500), Gly-His-Lys (GHK-Cu), Lys-Pro-Val (KPV)
CHEMICAL STRUCTURE
Molecular Formula: C62H98N16O22 (BPC-157), C212H350N56O78S (TB500), C28H46CuN12O8 (GHK-Cu), C18H34N4O6 (KPV)
Source: PubChem
Mechanism of Action
The KLOW blend acts on multiple cellular pathways that regulate inflammation, tissue repair, angiogenesis, and oxidative balance. BPC-157 enhances nitric oxide and VEGF signaling to promote angiogenesis and fibroblast activation. TB-500 regulates actin polymerization, enabling cell migration and cytoskeletal remodeling during tissue repair. GHK-Cu provides antioxidant and anti-fibrotic activity by modulating inflammatory cytokines, stimulating collagen synthesis, and promoting copper-dependent enzymatic repair. KPV complements these mechanisms by suppressing NF-?B activity, reducing TNF-? and IL-6 levels, and supporting epithelial integrity. Together, these peptides act synergistically to accelerate healing, reduce inflammation, and strengthen tissue resilience1-5.
1
Promotion of Angiogenesis: BPC-157 activates vascular endothelial growth factor (VEGF) and nitric oxide (NO) pathways, stimulating new capillary formation and improving blood supply to damaged tissues.
This enhances oxygenation and nutrient delivery to accelerate healing1.
2
Stimulation of Fibroblast Migration and Collagen Production: Both BPC-157 and TB-500 increase fibroblast activity and collagen synthesis, leading to stronger extracellular matrix formation and faster wound closure.
These actions also support tendon and ligament repair1,2.
3
Regulation of Actin Polymerization: TB-500 regulates actin dynamics and cytoskeletal organization, enabling efficient cell migration and tissue remodeling at the site of injury.
This mechanism supports regeneration across muscle, skin, and connective tissues2.
4
Antioxidant and Anti-Fibrotic Effects: GHK-Cu provides copper-dependent activation of superoxide dismutase (SOD) and other antioxidant enzymes that neutralize reactive oxygen species.
It also suppresses TGF-alpha/Smad2/3 signaling to reduce fibrotic tissue formation and promote balanced remodeling3.
5
Modulation of Inflammatory Cytokines: KPV acts as a potent anti-inflammatory tripeptide by inhibiting nuclear factor kappa-B activation and reducing production of TNF-alpha IL-beta, and IL-6.
This decreases inflammatory cell infiltration and protects surrounding tissues from secondary damage4.
6
Epithelial Barrier Protection: KPV enhances epithelial and mucosal integrity by supporting tight-junction proteins and reducing permeability during inflammation.
This helps restore homeostasis in both skin and gut tissues4.
7
Copper-Dependent Cellular Repair: The GHK-Cu complex delivers bioavailable copper ions essential for enzymatic repair processes, including lysyl oxidase-mediated cross-linking of collagen and elastin, which improves tissue elasticity and resilience3.
Biological Activity
KLOW exerts its biological effects through coordinated action across cellular repair, inflammation regulation, and oxidative protection pathways. BPC-157 and TB-500 promote angiogenesis and fibroblast activation, stimulating new vessel formation and collagen deposition. GHK-Cu enhances extracellular matrix remodeling, increases antioxidant enzyme activity, and reduces fibrosis. KPV reinforces these effects by suppressing pro-inflammatory cytokines and protecting epithelial and mucosal barriers from immune-mediated damage. Together, these actions accelerate wound healing, improve tissue strength and elasticity, and support homeostatic recovery following injury or inflammation1,5.
Storage
- Store at −20°C, protect from light and moisture. Reconstitute in sterile saline or PBS (pH ~7.4). Avoid repeated freeze-thaw cycles.
Drug Categories
Regenerative and anti-inflammatory peptide complex; angiogenic and tissue-repair blend; antioxidant and cytoprotective peptide formulation.
Additional Notes
- Suitable for both in vitro and in vivo research applications
Summary Table
Property
Description
CAS Number
137525-51-0 (BPC-157), 77591-33-4 (TB500), 300801-03-0 (GHK-Cu), 2828433-34-5 (KPV)
Molecular Formula
C62H98N16O22 (BPC-157), C212H350N56O78S (TB500), C28H46CuN12O8 (GHK-Cu), C18H34N4O6 (KPV)
Molecular Weight (MW)
~7189 g/mol
Mechanism of Action
Promotes angiogenesis, actin polymerization, collagen synthesis, and NF-?B inhibition
Biological Activity
Enhances tissue repair, reduces inflammation, and supports epithelial and vascular integrity
Supplied Form
Lyophilized powder
Purity
≥99% (HPLC)
Storage
−20°C, protect from light and moisture
Drug Categories
Regenerative and anti-inflammatory peptide complex; angiogenic and tissue-repair blend; antioxidant and cytoprotective peptide formulation.
Additional Notes
For research use only
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
The KLOW Peptide Blend is an advanced regenerative and anti-aging formulation that combines four synergistic peptides (BPC-157, TB-500, GHK-Cu, and KPV) to promote cellular renewal, tissue resilience, and youthful biological function. Each peptide targets a distinct aspect of the aging process, working together to restore structural integrity, reduce inflammation, and enhance cellular vitality. BPC-157 supports systemic regeneration by stimulating angiogenesis, improving microcirculation, and promoting fibroblast migration. These actions enhance nutrient and oxygen delivery to aging tissues, encouraging collagen renewal and improved elasticity. Through modulation of nitric oxide and growth factor pathways, BPC-157 helps counteract age-related vascular decline and supports repair at the cellular level. TB-500 complements this process by regulating actin polymerization, a critical mechanism for cell motility, differentiation, and tissue remodeling. Its ability to enhance cellular communication and structural regeneration contributes to improved skin texture, muscle tone, and wound recovery. GHK-Cu provides potent anti-aging and antioxidant benefits by activating genes associated with collagen and elastin production, antioxidant defense, and cellular repair. It stimulates the synthesis of key extracellular matrix components while neutralizing reactive oxygen species, restoring firmness and reducing oxidative damage that accelerates visible and molecular aging. Finally, KPV, a C-terminal tripeptide fragment of ?-MSH, introduces targeted anti-inflammatory protection. It inhibits NF-?B activation and reduces inflammatory cytokines such as TNF-? and IL-6, mitigating the chronic low-grade inflammation (“inflammaging”) that contributes to tissue breakdown and cellular senescence. KPV also supports epithelial and mucosal barrier health, helping maintain systemic resilience and reducing oxidative burden throughout the body. Together, these peptides act on core hallmarks of aging: inflammation, oxidative stress, mitochondrial decline, and extracellular matrix degradation. The KLOW blend helps rejuvenate the cellular environment by promoting tissue regeneration, improving vascular and collagen integrity, and supporting antioxidant and immune balance. Through these mechanisms, it provides a comprehensive anti-aging and restorative foundation that enhances vitality, recovery, and structural longevity at the molecular and tissue levels1-5.
Research Highlights
Stimulates Angiogenesis and Fibroblast Activity: BPC-157 promotes blood vessel formation and fibroblast migration through activation of the VEGF and nitric oxide pathways, accelerating tissue regeneration and counteracting age-related vascular decline1.
Enhances Cellular Migration and Cytoskeletal Remodeling: TB-500 regulates actin polymerization and cytoskeletal dynamics, enabling efficient cell motility and structural repair during tissue regeneration2.
Stimulates Collagen and Elastin Synthesis: GHK-Cu upregulates genes associated with collagen, elastin, and glycosaminoglycan production, improving skin firmness and extracellular matrix integrity3.
Protects Against Oxidative Stress: GHK-Cu activates superoxide dismutase (SOD) and other copper-dependent antioxidant enzymes, reducing reactive oxygen species and preventing oxidative damage to aging cells3.
Reduces Inflammation and Cytokine Activity: KPV inhibits NF-?
B activation and suppresses the release of TNF-?, IL-1?, and IL-6, decreasing chronic low-grade inflammation linked to aging and tissue degeneration4.
Pharmacokinetic Profile
Route of Administration
SC
Dosing Frequency
Daily
Half-Life
1hr
- Route of Administration: SC (preclinical models)
- Dosing Frequency: Daily for 7-10 days
- Half-Life: Short, <1hr
Formulation & Handling
- Reconstitute in sterile saline for in vivo/in vitro use
- Store at −20°C, protect from light and repeated freeze-thaw cycles
- Shelf-stable for 12 months under proper conditions
Clinical Trial Activity
KLOW blend is a research-grade compound that has been studied in laboratory and early-stage human settings but has not undergone full clinical development. It is not approved for therapeutic use in humans, and no large-scale clinical trials have been conducted to evaluate its safety or efficacy as a medication. KLOW blend is supplied strictly for laboratory research and investigational purposes only.
References
1
Sikiric, P. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology 7, 1–14 (1999)
2
Maar, K. et al. Utilizing developmentally essential secreted peptides such as thymosin beta-4 to remind the adult organs of their embryonic state—new directions in anti-aging regenerative therapies. Cells 10, 1343 (2021).
3
Dou, Y. et al. The potential of GHK as an anti-aging peptide. Aging Pathobiol. Ther. 2, 58–61 (2020).
4
Getting, S. J., Schiöth, H. B. & Perretti, M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) ?-melanocyte-stimulating hormone peptides. J. Pharmacol. Exp. Ther. 306, 631–637 (2003).
5
Freeman, D. X. The Peptide Protocols Master Bible: Evidence-Based Guide Made Simple to Next-Generation Peptides & Combos – Usage, Dosing & Cycling for Weight Loss, Muscle Growth, Longevity & Body Optimization. Benjamin Bautista Publishing (2025).
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart Related products
Cagrilintide/GLP-1 Blend 5+5mg
Summary Description: Cagrilintide and semaglutide are two structurally unrelated peptide-based therapeutic agents (an amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist, respectively). The co-administration of cagrilintide and semaglutide leverages their complementary mechanisms for enhanced weight management and glycemic control, promoting significant reductions in bodyweight and improvements in metabolic health in populations with overweight, obesity, and type 2 diabetes1-3.
Products will arrive in a lyophilized (powder) form for maximum stability
GHK-Cu 50mg
Summary Description: GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It has potent tissue remodeling, wound healing, antioxidant, and anti-inflammatory properties. GHK-Cu stimulates collagen and glycosaminoglycan synthesis, modulates inflammation, promotes angiogenesis, and supports tissue regeneration and repair. It has been widely studied for applications in dermatology, regenerative medicine, and aging-related research for its role in tissue rejuvenation and healing1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 10mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 5mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
Retatrutide 10mg
Summary Description: Retatrutide is a next-generation investigational medication initially developed for the treatment of obesity and type 2 diabetes, with emerging evidence highlighting its potential multi-system benefits. Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist. This means it simultaneously activates the receptors for GIP, glucagon-like peptide-1 (GLP-1), and glucagon. Through this triple-receptor agonism, retatrutide not only lowers blood glucose levels and enhances insulin sensitivity but also suppresses appetite, increases energy expenditure, and reduces body weight. Early clinical studies suggest that retatrutide may improve cardiometabolic profiles by reducing blood pressure and improving lipid levels, further underscoring its promise for addressing both metabolic and cardiovascular risk factors in individuals with obesity and diabetes.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 10mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 20mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 10mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4
Products will arrive in a lyophilized (powder) form for maximum stability